ArticleNature communications2025
Physiological activation of Aryl hydrocarbon receptor by food-derived ligands is essential for the efficacy of anti-PD1 therapy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Therapeutic Potential of Polysaccharide-Modulated Gut Microbiota-Immune Axis in Gastrointestinal Cancers: Modern Insights From Traditional Pharmacy.Molecular nutrition & food research · 2026Review
- Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.Pharmacological reviews · 2026Review
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- Context-dependent functions of the aryl hydrocarbon receptor in gastrointestinal cancers: from microenvironmental regulation to precision targeted therapy.Frontiers in cell and developmental biology · 2026Review
- Systemic nutritional status and its dynamic changes as predictors of response to neoadjuvant immunotherapy in locally advanced MSS/pMMR colorectal cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Cancer immuno-surveillance and response to therapy are affected by environmental factors, including nutrition. However, the direct effects of individual nutrients remain poorly understood. Here we investigate the impact of dietary ligands of Aryl hydrocarbon receptor (AhR), a transcription factor activated by tryptophan catabolites generated through food digestion and microbiota metabolism. By analyzing pre-clinical tumor models in mice fed on a diet naturally poor in AhR ligands or the same diet supplemented with Indole-3-carbinol, we show that diet-derived AhR ligands are required for the optimal efficacy of anti-PD1 therapy. Using conditional knockout mice, we evidence an essential role for AhR in CD8 T cells, but not NK cells or myeloid cells. Mechanistically, AhR promotes anti-PD1-mediated reinvigoration of progenitor exhausted CD8 T cells and licences the functional response of effector CD8 T cells. Our work allows a better understanding of the role of nutrients in anti-tumor immune responses and has implications for the rational design of dietary interventions for improving the efficacy of checkpoint blockade therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.